Citadel Advisors
RANI icon

Citadel Advisors’s Rani Therapeutics RANI Stock Holding History

Citadel Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
276,600
+63,100
+30% +$80.6K ﹤0.01% 11395
2025
Q4 		$288K Buy
+213,500
New +$322K ﹤0.01% 10234
2025
Q3 		– Sell
-14,000
Closed -$7.2K – 13855
2025
Q2 		$7.2K Sell
14,000
-7,300
-34% -$5.96K ﹤0.01% 12219
2025
Q1 		$26.8K Buy
21,300
+18,000
+545% +$26.6K ﹤0.01% 12915
2024
Q4 		$4.52K Buy
3,300
+800
+32% +$1.68K ﹤0.01% 13925
2024
Q3 		$5.4K Buy
2,500
+500
+25% +$1.43K ﹤0.01% 13494
2024
Q2 		$7.6K Sell
2,000
-5,400
-73% -$28K ﹤0.01% 13237
2024
Q1 		$23K Buy
+7,400
New +$25.4K ﹤0.01% 12914
2023
Q3 		– Sell
-3,200
Closed -$13.2K – 14960
2023
Q2 		$13.2K Buy
3,200
+2,200
+220% +$10.2K ﹤0.01% 13049
2023
Q1 		$5.16K Buy
+1,000
New +$6.01K ﹤0.01% 13888

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Citadel Advisors's RANI Position: Q4 2025 in Review

Citadel Advisors sold out of Rani Therapeutics (RANI) in Q4 2025, closing a stake of 452,542 shares — an estimated $683K sold.

Citadel Advisors first reported a position in RANI in Q1 2023 and held it in 8 quarters. The position peaked at $226K in Q3 2025. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • Citadel Advisors reported no remaining Rani Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 452,542 Rani Therapeutics shares in Q4 2025, an estimated $683K.
  • Citadel Advisors first reported a position in Rani Therapeutics in Q1 2023 and held it in 8 quarters.
  • Citadel Advisors's Rani Therapeutics position peaked at $226K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.